➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Express Scripts
McKesson
McKinsey
Johnson and Johnson

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 8,563,269

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,563,269
Title:Modified antibody compositions, methods of making and using thereof
Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Inventor(s): Stagliano; Nancy E. (Santa Barbara, CA), West; James W. (Santa Barbara, CA), Kamath; Kathryn (Santa Barbara, CA), Bessette; Paul H. (Camarillo, CA), Gluck; Frederick W. (Santa Barbara, CA), Sagert; Jason (Santa Barbara, CA), Daugherty; Patrick (Santa Barbara, CA)
Assignee: CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/315,623
Patent Claims:see list of patent claims

Details for Patent 8,563,269

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 2006-09-27 ⤷  Free Forever Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 2004-06-18 ⤷  Free Forever Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX Orphan search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 1978-01-16 ⤷  Free Forever Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,563,269

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2010081173 ⤷  Free Forever Trial
United States of America 10059762 ⤷  Free Forever Trial
United States of America 10118961 ⤷  Free Forever Trial
United States of America 10875913 ⤷  Free Forever Trial
United States of America 2010189651 ⤷  Free Forever Trial
United States of America 2012149061 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Express Scripts
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.